MAL-dPEG®12-DSPE, product number 11028, is designed for development of liposomes and micelles. The polyethylene glycol (PEG) unit on the molecule is a single molecular weight discrete PEG (dPEG®). The molecular weight of the entire molecule, including the lipophilic tail, is 1499 Daltons. The dPEG® terminus is functionalized with a maleimidopropyl group. The lipophilic tail of the molecule contains 1, 2-Distearoyl-sn-glycero-3-phosphoethanolamine (DSPE) for insertion into a liposomal membrane.

Liposomes and micelles are widely used for payload delivery, including peptides and small molecule drugs, and in imaging applications. Without PEG, liposomes and micelles clear quickly from the blood via the reticuloendothelial system (RES). A sufficiently dense coating of PEG creates a hydrophilic, flexible, steric barrier around the PEGylated liposomes and micelles, thus preventing opsonin proteins from binding to the liposomal/micellar surface (opsonization). Consequently, liposomes and micelles circulate longer in the bloodstream, which therefore results in lower dosing requirements. DSPE-PEG is one of the most studied lipid-PEG conjugates used in liposomes and micelles.

Unlike traditional, disperse polymer PEGs (Đ > 1), Quanta BioDesign’s dPEG® products are designed as single molecular weight products with discrete chain lengths (Đ = 1). This simplifies product analysis because there is no intractable mixture of chain lengths and molecular weights as is the nature of polymeric PEGs. Click here to learn more about our dPEG® technology. Simplified product analysis saves time and money for cost conscious companies seeking to develop new delivery technologies for diagnostic, therapeutic, or imaging applications. A popular, competitive product that is currently marketed uses polymeric PEG and is more difficult to analyze and characterize than PN11028.

The maleimide functional group at the terminus of MAL-dPEG®12-DSPE can react with a free thiol group to conjugate a drug or small molecule on the surface of the liposome or micelle. Furthermore, at least one study suggests that a small amount of surface modification with maleimide enhances cellular uptake of liposomes or micelles and consequent drug delivery by inducing thiol-mediated membrane trafficking.

If you need bulk product in a larger package size than our standard sizes, please contact us for a quote. Our commercial capabilities permit us to manufacture this product at any scale that you need.

Application References:

  1. Hermanson, G. T. Chapter 18, PEGylation and Synthetic Polymer Modification. Bioconjugate Techniques, 3rd edition. Academic Press: New York, 2013, 787-838. Click here now for a review of Greg’s book and a link to purchase it.
  2. Hermanson, G. T. Chapter 21, Liposome Conjugates and Derivatives. Bioconjugate Techniques, 3rd edition. Academic Press: New York, 2013, 921-949.
  3. Che, J.; Okeke, C. I.; Zhong-Bo, H. and Xu, J. DSPE-PEG: A Distinctive Component in Drug Delivery System. Curr Pharm Design, 2015, 21(12), 1598-1605.
  4. Zalipsky, S. Chemistry of Polyethylene-Glycol Conjugates with Biologically-Active Molecules. Adv Drug Deliv Rev, 1995, 16(2-3), 157-182.
  5. Parr, M. J.; Ansell, S. M.; Choi, L. S.; Cullis, P. R. Factors Influencing the Retention and Chemical Stability of Poly(Ethylene Glycol)-Lipid Conjugates Incorporated into Large Unilamellar Vesicles. Biochimica et Biophysica Acta (BBA) – Biomembranes, 1994, 1195(1), 21–30.
  6. Pozzi, D.; Colapicchioni, V.; Caracciolo, G.; Piovesana, S.; Capriotti, A. L.; Palchetti, S.; Grossi, S. D.; Riccioli, A.; Amenitsch, H.; Laganà, A. Effect of Polyethyleneglycol (PEG) Chain Length on the Bio–Nano-Interactions between PEGylated Lipid Nanoparticles and Biological Fluids: From Nanostructure to Uptake in Cancer Cells. Nanoscale, 2014, 6(5), 2782–2792.
  7. Sugiyama, I.; Sadzuka, Y. Change in the Character of Liposomes as a Drug Carrier by Modifying Various Polyethyleneglycol-Lipids. Biological and Pharmaceutical Bulletin, 2013, 36(6), 900–906.
  8. Li, T.; Takeoka, S. Enhanced Cellular Uptake of Maleimide-Modified Liposomes via Thiol-Mediated Transport. Int J Nanomedicine, 2014, 9, 2849–2861.
  9. Mitchell, N.; Kalber, T. L.; Cooper, M. S.; Sunassee, K.; Chalker, S. L.; Shaw, K. P.; Ordidge, K. L.; Badar, A.; Janes, S. M.; Blower, P. J.; et al. Incorporation of Paramagnetic, Fluorescent and PET/SPECT Contrast Agents into Liposomes for Multimodal Imaging. Biomaterials, 2013, 34(4), 1179–1192.
  10. Zhang, L.; Chan, J. M.; Gu, F. X.; Rhee, J.-W.; Wang, A. Z.; Radovic-Moreno, A. F.; Alexis, F.; Langer, R.; Farokhzad, O. C. Self-Assembled Lipid−Polymer Hybrid Nanoparticles: A Robust Drug Delivery Platform. ACS Nano, 2008, 2(8), 1696–1702.
  11. Hadinoto, K.; Sundaresan, A.; Cheow, W. S. Lipid–Polymer Hybrid Nanoparticles as a New Generation Therapeutic Delivery Platform: A Review. European Journal of Pharmaceutics and Biopharmaceutics, 2013, 85(3, Part A), 427–443.

Additional information

Weight N/A
Dimensions N/A